Scn1a+/- mice are used to study seizure phenotypes associated with reduced Nav1.1 function. This article covers the phenotypes established in published mouse studies, endpoints for pharmacology work, the large effect of genetic background, and one verified R613X strain identifier.[S1][S2][S4]
What the model represents
Scn1a encodes the voltage-gated sodium-channel alpha subunit Nav1.1. In a foundational mouse study, heterozygous loss of Scn1a produced spontaneous seizures and sporadic deaths beginning after postnatal day 21, while homozygous-null mice developed ataxia and died at approximately postnatal day 15.[S1] These are mouse phenotypes. A candidate that changes them has shown activity in that experimental system, not clinical efficacy in Dravet syndrome.
Study questions and endpoints
Study question
Endpoints in the mouse
Antiseizure pharmacology
Spontaneous electrographic seizures, hyperthermia-induced seizure threshold, and survival when prospectively justified[S1][S2]
Target-restoration approaches
Scn1a transcript or Nav1.1 protein, target-cell electrophysiology, and seizure endpoints appropriate to the intervention[S1]
Sudden unexpected death in epilepsy
Seizure-linked physiology, terminal events, and survival analysis[S3]
Associated motor or behavioral phenotypes
Predefined motor or behavioral measures, with seizure burden and treatment-related sedation considered as confounders
Seizure burden and survival can be important endpoints, but neither should be selected automatically. The primary endpoint must match the mechanism, observation window, expected event rate in the exact genetic background, and welfare stopping rules.
Method
What to predefine
Electroencephalography
Recording duration, seizure definition, event adjudication, frequency, duration, and whether scoring is blinded
Hyperthermia-induced seizure test
Heating method, rate of temperature increase, seizure-stage definition, threshold temperature, and stopping rule
Patch-clamp electrophysiology
Cell identity, sodium-current metric, recording conditions, and linkage to target restoration
Behavioral testing
Motor, activity, and social measures; timing relative to seizures and dosing; sedation and motor impairment as confounders
Yu and colleagues reported ataxia and death around postnatal day 15 in Scn1a-/- mice. Scn1a+/- mice developed spontaneous seizures and sporadic deaths after postnatal day 21, with marked dependence on genetic background.[S1]
In hippocampal recordings, sodium-current density was reduced in GABAergic inhibitory interneurons but not in excitatory pyramidal neurons. The authors linked impaired inhibitory-neuron excitability to network hyperexcitability in the mouse model.[S1] Separate work used Scn1a-mutant mice to investigate physiological events associated with sudden unexpected death in epilepsy.[S3]
Verifying the exact strain
Do not select a colony from a search ranking. Confirm the allele, formal strain name, stock identifier, background, breeding state, and phenotype documentation against the source record before study start.
R613X strain record
The official strain record for 129S1/SvImJ-Scn1aem1Dsf/J, nicknamed SCN1A[R613X]; Dravet model #10, is Stock No. 034129. The record specifies an A-to-T change at nucleotide 1837 that converts arginine 613 to a stop codon.[S4]
Specify the exact allele and background before comparing proposals. Require historical seizure and survival data for that colony, define electrographic and behavioral endpoints prospectively, and plan welfare monitoring around the expected event window. Treat every positive result as evidence in that mouse model and background, not as proof of benefit in patients.
References
Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. https://doi.org/10.1038/nn1754 (accessed 2026-09-03)
C57BL/6J and C57BL/6N substrains differentially influence phenotype severity in the Scn1a+/- mouse model of Dravet syndrome. https://doi.org/10.1002/epi4.12287 (accessed 2026-09-03)
3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise
In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.
Pharmacology (Efficacy) StudiesDisease-Relevant Models for Translational Drug Evaluation
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)
SMC Laboratories, Inc.
SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.
Areas of Expertise
Disease-Relevant Model Portfolio
SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.
Study Design Based on Target Biology
Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.
Support from Target Validation to Proof of Concept
With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.
Safety StudiesComprehensive Safety Assessment for Preclinical Development
Reference: Charles River Laboratories official website (https://www.criver.com/)
Charles River Laboratories
Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.
Areas of Expertise
General Toxicology Across Study Designs
Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.
Non-GLP and GLP Study Support
Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.
Integrated IND-Enabling Safety Assessment
Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.
Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with Pharmacological Response
Reference: Inotiv official website (https://www.inotiv.com/)
Inotiv
Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.
Areas of Expertise
Pharmacokinetic Characterization
PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.
Exposure–Response Evaluation
Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.
Integrated DMPK and Development Support
Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.
Japanese
